Diabetes Diagnosis and Management 2016

ACCREDITATION STATEMENT

This activity has expired and is no longer available for CME credit or ABIM MOC points.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners will be able to:

Assessment of Cardiovascular Risk in Diabetes: A Cardiologist’s Perspective

  • Compare the effectiveness of established CVD prevention treatments in T1D and T2D versus the non-diabetic at-risk population
  • Evaluate clinical practice guidelines on the prevention, screening and management of comorbidities
  • Effectively manage cardiovascular autonomic neuropathy in T2D patients

Where Does Bariatric Surgery Fit in the Treatment and Cure of Diabetes?

  • Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience
  • Select appropriate medical therapy options for the co-management of diabetes and obesity
  • Recognize the appropriate provocative test to evaluate hypoglycemia from bariatric surgery

Goals for Blood Pressure and Lipids: How Did We Get There?

  • Discuss the strategy and rationale of the new AHA/ACC guidelines
  • Identify blood pressure treatment targets and preferred pharmacologic treatment options for patients with diabetes
  • Discuss the recent advances in the management of hyperlipidemia
  • Compare the pros and cons of follow-up measurements in the management of lipids in T2D
  • Describe the effectiveness of various classes of lipid-modifying therapies for CVD treatment and prevention in T2D

Legacy Effect, Timing and Duration of Glycemic Control: What Can We Learn From the Long-Term Cardiovascular Trials?

  • Describe the changing epidemiologic features of CVD risk factors and CVD events in diabetes
  • Synthesize the availability of clinical tests of cardiovascular trials for glycemic control

Science of Autoimmune Pathogenesis of Diabetes

  • Discuss the new immunization recommendations for patients with diabetes

Current Status for Prevention and Early Intervention Trials in Type 1 Diabetes

  • Evaluate clinical practice guidelines for the management of diabetes and its comorbidities and predict how these may evolve in light of new data and clinical experience
  • Discuss how new clinical studies can improve their patients’ health

Biology of Fetal Islet Beta-Cell Development and Feasibility of Stem Cell Therapy

  • Discuss the recent studies on islet transplantation
  • Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience
  • Recognize the progression of beta-cell dysfunction in the pathophysiology of T2D

Management of Diabetic Peripheral Neuropathy

  • Screen patients for early clinical signs of neuropathy
  • Utilize protective measures to prevent foot ulcers, falls, and other morbidities that are the result of diabetic neuropathy
  • Identify available interventions specific to each neurologic impairment

Kidney Disease

  • Discuss the appropriate screening for patients with nephropathy
  • Determine the best treatment options for patients with diabetic nephropathy
  • Identify pharmacologic solutions to delay progression of nephropathy

Management of Lipids in Patients with Diabetes

  • Manage hypertriglyceridemia in a diabetic patient
  • Recognize the importance of multidisciplinary teams in the treatment of hyperlipidemia
  • Develop a treatment strategy to address steadily increasing hypertriglyceridemia associated with worsening control of diabetes
  • Treat hyperlipidemia in patients with pharmaceutical sensitivities
  • Discuss the recent advances in the management of hyperlipidemia

Technological Advances in Treatment of Type 1 Diabetes

  • Explain the role new agents have in meeting current therapeutic challenges, including individualizing care for patients
  • Compare and critique current glycemia algorithms and discuss the place for new therapies within them

Type 1 Diabetes Management in Children

  • Determine the most effect treatment strategies for managing type 2 diabetes in children
  • Recognize patient barriers to medication adherence and suggest strategies to overcome them
  • Identify pitfalls in insulin pump therapy
  • Utilize insulin-dosing guidelines to adjust insulin regimen

TARGET AUDIENCE

This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, endocrine physician’s assistants and internal medicine physicians who treat diabetes, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

STATEMENT OF INDEPENDENCE

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The commercial supporters of this activity have no influence over the planning of this CME activity.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Harold Bays, MD: Consultant, Alnylam, ISIS; Consultant & Investigator, Eli Lilly & Company, Merck & Co., Novartis; Consultant & Speaker, Regeneron, Sanofi, Takeda; Consultant, Investigator, & Speaker, Amgen; Investigator, Ardea, Arisaph, Bristol Meyers Squibb, Catabasis, Cymabay, Elcelyx, Esperion, Gilead, GSK, Hanmi, Hisun, Hoffman LaRoche, Home Access, Janssen, Johnson and Johnson, Necktar, Novo Nordisk, Omthe; Investigator & Speaker, Amarin, AstraZeneca, Eisai
Carla Greenbaum, MD: Principal Investigator, Novo Nordisk
Lee Kaplan, MD, PhD: Investigator, Johnson & Johnson
Lori Laffel, MD, MPH: Scientific Board Member, Dexcom, Novo Nordisk, Roche Diagnostics, Sanofi
John Leahy, MD: Advisory Group Member, Johnson & Johnson, Merck, Novo Nordisk, Sanofi
Jorge Plutzky, MD: Consultant, Amylin Pharmaceuticals, Astra Zeneca, Daiichi Sankyo, Eli Lilly, Ember Therapeutics, Roche/Genentech, Merck, NovoNordisk, Pfizer, Roche/Genentech, Takeda, Vivus; Consultant & Research Support, Bristol-Myers Squibb, GlaxoSmithKline
Peter Reaven, MD: Advisory Group Member, Amgen, Sanofi
James Russell, MBChB, MS: Investigator, Department of Veterans Affairs, National Institutes of Health, Impeto Medical
Matthias von Herrath, MD: Employee, Novo Nordisk
Howard Wolpert, MD: Consultant, Insulet, Novo Nordisk; Investigator, Abbott Laboratories, Dexcom; IP and other activities, Glooko
Carol Wysham, MD: Advisory Group Member, Investigator, & Speaker, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Janssen, Sanofi; Investigator & Speaker, Novo Nordisk
The following faculty reported no relevant financial relationships: Maryam Afkarian, MD, PhD; Matthias Hebrok, PhD; Marc Jaffe, MD; Jane Reusch, MD
The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such off-label use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

The live activity from which these session recordings are derived was supported by educational grants from Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; and Novo Nordisk Inc.*
*As of March 23, 2016

AMA PRA CATEGORY 1 CREDIT™ (CME) AND ABIM MOC POINTS INFORMATION

This activity has expired and is no longer available for CME credit or ABIM MOC points.

SYSTEM REQUIREMENTS

Your system must meet the following requirements:
Computer: with minimum processor and memory as recommended by operating system manufacturer
Operating System: Windows: 7, 8, 10. Macintosh OSX
Internet Browser: consult the detailed system requirements page to determine the browser version required by Adobe Flash on your computer’s operating system.
Players & Plugins: an up-to-date version of Adobe Flash Player
Audio: Functioning sound card with attached speakers installed
Internet Connection: a broadband Internet connection
Please review the detailed system requirements page for more information and troubleshooting steps.
LAST REVIEW DATE: March 23, 2016
ACTIVITY RELEASE DATE: April 2016
ACTIVITY EXPIRATION DATE: March 31, 2017 (date after which this enduring material is no longer certified for AMA PRA Category 1 Credits™ or ABIM MOC points)
For technical assistance or information, please contact support@endosessions.org.
For questions about content or obtaining CME credit or MOC points, please contact the Endocrine Society at education.endocrine.org/contact.